Strom, Nora I. http://orcid.org/0000-0002-5261-8852
Burton, Christie L. http://orcid.org/0000-0002-8955-6528
Iyegbe, Conrad
Silzer, Talisa
Antonyan, Lilit
Pool, René http://orcid.org/0000-0001-5579-0933
Lemire, Mathieu
Crowley, James J. http://orcid.org/0000-0001-9051-1557
Hottenga, Jouke-Jan http://orcid.org/0000-0002-5668-2368
Ivanov, Volen Z.
Larsson, Henrik http://orcid.org/0000-0002-6851-3297
Lichtenstein, Paul http://orcid.org/0000-0003-3037-5287
Magnusson, Patrik http://orcid.org/0000-0002-7315-7899
Rück, Christian http://orcid.org/0000-0002-8742-0168
Schachar, Russell
Wu, Hei Man http://orcid.org/0000-0003-1559-7586
Cath, Danielle
Crosbie, Jennifer
Mataix-Cols, David http://orcid.org/0000-0002-4545-0924
Boomsma, Dorret I. http://orcid.org/0000-0002-7099-7972
Mattheisen, Manuel http://orcid.org/0000-0002-8442-493X
Meier, Sandra M.
Smit, Dirk J. A. http://orcid.org/0000-0001-8301-8860
Arnold, Paul D. http://orcid.org/0000-0003-2496-4624
Article History
Received: 15 November 2022
Revised: 18 January 2024
Accepted: 15 February 2024
First Online: 28 March 2024
Competing interests
: DM-C receives royalties for contributing articles to UpToDate, Wolters Kluwer Health, outside of the submitted work. RJS has consulted to E. Lilly, Highland Therapeutics and eHave. HL reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. HL is editorin-chief of JCPP Advances. PA receives research funding from Biohaven Pharmaceuticals, unrelated to the submitted work. All other authors report no potential conflict of interest.